Zhejiang LangHua Pharmaceutical Co.,LTD.
©Viva Biotech (Shanghai) Ltd. 沪ICP备12042930号 Powerd by 300.cn
Incorporated in the PRC and commenced operation in an office
Viva Biotech Shanghai was recognized as a Technically Advanced Service Enterprise.
• Viva Biotech Shanghai was recognized as a High-tech Enterprise.
• Filed three patents on fusion expression of membrane proteins and ASMS screening methodology with purified membrane proteins.
A record of 1000 new drug target proteins were studied by us with over 7000 independent crystal structures delivered.
Obtained pathogenic microorganism laboratory filing certificate.
Developed G-protein-coupled receptors (“GPCR”) membrane protein targets technology platform.
Commenced the construction of a research center in Jiaxing, Zhejiang Province.
• Avenue Capital Group became our strategic investor.
• Established the Department of Chemistry and Department of In-vitro Assay and started providing structure-based drug discovery services.
Developed a 6,000-membered library targeting GPCR and started to offer screening services.
Developed a proprietary fragment compound library and the ASMS screening technology and integrated with SBDD services.
Viva Biotech Holdings listed on the main board of the Hong Kong Stock Exchange. ( stock code: 1873.HK )
One of our clients announced a Phase I study in patients of a compound developed from scratch with considerable effort from our scientists utilizing SBDD.